Brief cognitive behavioral therapy appears promising for head and neck cancer survivors with body-image distress

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception.

August 14, 2026

Vol.52 No.32

By Viktor Clark, Sean M. Dozier, AnnaLynn M. Williams, Cynthia M. Rand and Lee A. Kehoe

Regulatory News

FDA final guidance on psychedelics opens the door to psycho-oncology research
Guidance permits treatment without psychotherapy, alarming scientists, advocates

FDA has released a final guidance for drug sponsors conducting clinical trials of psychedelics, including psilocybin, LSD, and MDMA, for the treatment of psychiatric and substance abuse disorders.

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Drugs & Targets

FDA grants Breakthrough Therapy designation to Rybrevant Faspro in advanced head-and-neck cancer

FDA granted Breakthrough Therapy designation for subcutaneous amivantamab and hyaluronidase-lpuj as a monotherapy for the treatment of adults with head-and-neck squamous cell carcinoma that is recurrent or metastatic and human papillomavirus-unrelated after disease progression on or after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.

February 20, 2026

Vol.52 No.07

Clinical Roundup

Sylvester-led study focuses on rate of failure in head and neck cancer trials

Researchers from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and collaborators analyzed 692 clinical trials launched between 2000 and 2024.

January 23, 2026

Vol.52 No.03

Clinical Roundup

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

Patients with oropharyngeal cancers who were treated with proton therapy, compared to traditional radiation therapy saw a significant survival benefit, according to the findings from a phase III trial led by researchers at the University of Texas MD Anderson Cancer Center.

December 19, 2025

Vol.51 No.46

Brief cognitive behavioral therapy appears promising for head and neck cancer survivors with body-image distress

YOU MAY BE INTERESTED IN

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

FDA final guidance on psychedelics opens the door to psycho-oncology research
Guidance permits treatment without psychotherapy, alarming scientists, advocates

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

FDA grants Breakthrough Therapy designation to Rybrevant Faspro in advanced head-and-neck cancer

Sylvester-led study focuses on rate of failure in head and neck cancer trials

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Brief cognitive behavioral therapy appears promising for head and neck cancer survivors with body-image distress

YOU MAY BE INTERESTED IN

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical frameworkDevelopers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

FDA final guidance on psychedelics opens the door to psycho-oncology researchGuidance permits treatment without psychotherapy, alarming scientists, advocates

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

FDA grants Breakthrough Therapy designation to Rybrevant Faspro in advanced head-and-neck cancer

Sylvester-led study focuses on rate of failure in head and neck cancer trials

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

Never miss an issue!

Login

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

FDA final guidance on psychedelics opens the door to psycho-oncology research
Guidance permits treatment without psychotherapy, alarming scientists, advocates